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Novelty and impact of this paper. 
This work shows the ability of SPARC to exert novel antitumoral effects on human 
hepatocellular carcinoma cells. Cancer cells acquire a less aggressive-like phenotype 
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partially through the induction of a mesenchymal-to-epithelial transition. Transient 
forced SPARC overexpression in HCC cells led them more susceptible to standard 
chemotherapy. In addition, in vitro and in vivo results further suggest SPARC 
overexpression as an strategy for controlling HCC tumor growth.    
 
Abbreviations used: HCC: hepatocellular carcinoma; SPARC: Secreted protein, acidic 
and rich in cysteine; TAM: tumor associated macrophages; MET: mesenchymal-to-
epithelial transition; FBS, fetal bovine serum; TGF-β1, transforming growth factor beta 
1; rSPARC, recombinant human SPARC. 
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ABSTRACT   
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading 
cause of cancer-related death worldwide. Current treatments are extremely 
disappointing. SPARC (Secreted protein, acidic and rich in cysteine) is a matricellular 
glycoprotein with differential expression in several tumors, including HCC, which 
significance remains unclear. We infected HCC cells (HepG2, Hep3B and Huh7) with 
an adenovirus expressing SPARC (AdsSPARC) to examine the role of SPARC 
expression on HCC cells and its effect on tumor aggressiveness. The in vitro HCC cells 
substrate-dependent proliferation and cell cycle profile were unaffected; however, 
SPARC overexpression reduced HCC proliferation when cells were grown in spheroids. 
A mild induction of cellular apoptosis was observed upon SPARC overexpression. 
SPARC overexpression resulted in spheroid growth inhibition in vitro while no effects 
were found when recombinant SPARC was exogenously applied. Moreover, the 
clonogenic and migratory capabilities were largely decreased in SPARC-overexpressing 
HCC cells, altogether suggesting a less aggressive HCC cell phenotype. Consistently, 
AdsSPARC-transduced cells showed increased E-cadherin expression and a 
concomitant decrease in N-cadherin expression. Furthermore, SPARC overexpression 
was found to reduce HCC cell viability in response to 5-FU-based chemotherapy in 
vitro, partially through induction of apoptosis. In vivo experiments revealed that SPARC 
overexpression in HCC cells inhibited their tumorigenic capacity and increased animal 
survival through a mechanism that partially involves host macrophages. Our data 
suggest that SPARC overexpression in HCC cells results in a reduced tumorigenicity 
partially through the induction of mesenchymal-to-epithelial transition (MET). These 
evidences point to SPARC as a novel target for HCC treatment. 
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INTRODUCTION. 
HCC is the sixth most common cancer and the third leading cause of cancer-related 
death in the world 1. Unfortunately, the incidence and mortality associated with HCC is 
increasing steadily in USA as in Europe 2. Current curative options can be applied to a 
paucity of patients and, in general, the prognosis of HCC is dismal due to underlying 
cirrhosis as well as to poor tumor response to chemotherapeutic regime 3, 4. Therefore, 
novel therapies are urgently needed for advanced HCC 5.  
There is a complex cross-talk between cancer cells and different tumor 
microenvironmental components, such as fibroblasts, endothelial cells, tumor associated 
macrophages (TAM) and matricellular proteins 6. Accumulating evidence indicates that 
this dynamic cross-talk can modulate tumor cell capacity to invade and disseminate 6. It 
is therefore highly relevant to assess whether and how those environmental factors are 
able to regulate tumor cellular processes in cancer disease. With this regard and 
especially in the case of HCC, in which cirrhosis is the underlying disease of most 
patients 4, the focus is placed on analyzing cellular events triggered by cell-matrix 
interactions.  
SPARC, also named BM40 or osteonectin, is a secreted multifunctional matricellular 
glycoprotein involved in a wide number of biological processes during development, 
tissue repair and remodeling 7-10. Among them, it was shown to inhibit cell cycle in 
fibroblasts and endothelial cells, by arresting cells at G1 11. In certain cell types, SPARC 
has also been shown to reduce cell adhesion to integrin-ligand coated surfaces due to 
disruption of focal adhesion complexes, causing inhibition of cell spreading 12. SPARC 
is known to interact with several extracellular matrix components and to bind to, and 
modulate the expression and activity of several growth factors and matrix 
metalloproteinases 13-15. For instance, SPARC has been shown to induce anti-
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angiogenesis likely through blockade of the VEGF- and FGF-2 induced endothelial cell 
proliferation, or to block tumor stromal cell growth through inhibition of PDGF activity 
16-18
.  
Changes in SPARC expression levels were evidenced in several malignant tumors of 
epithelial and non-epithelial origin 19-22. Nevertheless, the role of SPARC in cancer is 
controversial and it seems to depend on the type of tumor 23. For example, 
overexpression of SPARC in neuroblastoma 24, pancreatic adenocarcinoma cells25, 
ovarian cancer 26, colorectal carcinoma 27 and acute myeloid leukemia 28 was associated 
with good prognosis. Induction of cancer cell apoptosis  and enhanced sensitivity to 
chemotherapeutic drugs are mechanisms likely involved in the beneficial antitumoral 
effects observed upon SPARC enhanced expression in colon cancer cells 29.  
In spite of beneficial effects of SPARC overexpression in certain tumor types, the 
induction of SPARC has been positively associated with increased aggressiveness in 
melanoma 30, 31, glioblastoma 32, prostate 33 and breast cancer 34 . It seems that SPARC 
effects on different cancer types might depend on whether SPARC acts directly on 
tumor cells or indirectly, by influencing adjacent stromal cells 23.   
The expression of SPARC was shown to be induced in myofibroblasts of cirrhotic livers 
in HCV chronically infected patients 35 and in experimental liver cirrhosis 36. Similarly, 
SPARC overexpression was observed in HCC, along capillaries present in the tumor 
capsule 37. Lau et al. showed HCC antitumoral effects of SPARC forced expression in 
human tumor xenografts which correlated with a decreased neo-angiogenesis 22, but no 
mechanism was proposed. Thus, even though some authors showed SPARC 
overexpression in HCC 22, 35, 37, 38 and others reported some antitumor effects22 the 
significance of SPARC expression changes in HCC still remains unclear and the 
mechanisms involved, unknown.  
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Cadherins are a superfamily of transmembrane glycoproteins that mediate intercellular 
adhesion as well as other signaling events 39. Disruptions in E-cadherin expression have 
been associated with enhanced aggressiveness of certain types of tumors including HCC 
40-42
. Moreover, enhanced expression of mesenchymal-associated cadherins, such as N-
cadherin, in cancer cells increased tumor cell aggressiveness and facilitated tumor 
dissemination 43.  
In an effort to assess the role and action mechanisms of SPARC in HCC, we transiently 
overexpressed SPARC in HepG2 HCC cells by transduction with an adenoviral vector 
(AdsSPARC). Our results hereby show for the first time that a transient increase in 
SPARC expression levels on HCC cells reduced their spheroid growth, clonogenic, 
migratory and adherent capabilities. The in vivo growth capacity of SPARC- 
overexpressing HCC cells was strongly inhibited in nude mice, a feature now associated 
with an increased number of host macrophage cells. Interestingly, up-regulation of 
SPARC expression decreases HCC cell viability in response to 5-FU-based 
chemotherapy. More importantly, overexpression of SPARC was associated with an up-
regulation of E-cadherin and a consistent down-regulation of N-cadherin, a tandem that 
likely results in a less aggressive HCC cell phenotype. 
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MATERIAL AND METHODS.  
Generation of recombinant adenoviral vectors. 
AdsSPARC, a first-generation replication-defective adenovirus was constructed and 
produced as previously described 36. Briefly, a 1.7 kb Sa/I fragment containing the 
coding sequence of human SPARC or a 527 bp SalI fragment containing the bacterial β-
galactosidase gene were cloned in pADPSY-LTRSVpolyA vector to generate 
adenoviral vectors carrying SPARC cDNA in sense orientation (AdsSPARC) or Ad-
βgal, respectively. AdsSPARC and Ad-βgal were expanded in HEK-293 cells, purified 
by cesium chloride density gradient, desalted using a PD-10 Sephadex G-25 column 
(Amersham Biosciences, Piscataway, NJ), and stored at -80°C. The concentration of 
recombinant vector was expressed as 50% tissue culture infectious doses (TCID50) per 
milliliter 44. For SPARC downregulation experiments, adenoviral vectors carrying 
SPARC cDNA in antisense orientation (AdasSPARC) were generated and 
experimentally applied 36. 
 
Cells and cell culture. 
HepG2, Hep3B and HuH7 human hepatocellular carcinoma cells (kindly provided by 
Prof. Prieto, University of Navarra) were grown in Dulbecco’s Modified Eagles 
Medium (DMEM) supplemented with 10% v/v fetal bovine serum (FBS) and 
antibiotics. Cell cultures were maintained at 37C in a 5% CO2 humidified incubator. 
HCC cells, transduced with AdsSPARC, AdasSPARC or Adβgal at MOI of 100 or non-
transduced cells were used in different experiments. 
 
Immunofluorescence assays.  
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For immunofluorescence studies of SPARC expression HepG2 cells were fixed in 4% 
paraformaldehyde and blocked with 10 % goat serum in phosphate buffered saline 
(PBS)-0.2%Tween for 60 min at room temperature, followed by overnight incubation at 
4ºC in a humid chamber with a polyclonal rabbit anti-SPARC antibody (32 µg/mL; 
Hybridoma ). After 3 washes with PBS, bound antibodies were detected with FITC-
conjugated goat anti-mouse IgG (Jackson Immuno Research, West Grove, PA). 
Secondary antibody was diluted 1:40 in PBS-0.2% Tween and incubated for 2h at 37ºC. 
Nuclear morphology was examined by staining with DAPI. Images were captured from 
a Nikon E800 microscope coupled to a CCD camera. Control experiments without 
primary antibody showed only a faint background staining (not shown).  
 
Three-dimensional spheroids 
Ninety-six-well tissue culture plates were coated with 75 µl of 1% agarose in PBS. 
Nearly confluent non-transduced HCC, HCC/AdsSPARC, HCC/AdasSPARC or 
HCC/Ad-βgal (HepG2 and Hep3B) were washed twice with PBS, trypsinized, and 
seeded at 5x103 cells/well in 150 µl of 2% FBS DMEM  to obtain a single homotypic 
spheroid per well. Seventy-five microliters of supernatant were carefully removed from 
each well every 3 days and replaced with fresh medium. Spheroid size was measured at 
days 2  and 6 using an inverted microscope and photographed. Length and width were 
measured using the ImageJ program (NIH). Spheroid volume was expressed as arbitrary 
units. Non-infected HepG2 cells were seeded at 5x103 cells/well in 150 µl of 2 % FBS 
DMEM with or without 0,5 µg/ml of recombinant SPARC. Spheroids volume was 
measured as described above 
 
Proliferation assays and in vitro apoptosis assessment. 
Page 8 of 44
John Wiley & Sons, Inc.
International Journal of Cancer
 9 
Cell proliferation was measured using the colorimetric MTT assay (Invitrogen). Briefly, 
3x103 HCC cells (HepG2, Hep3B and Huh7)/well were seeded onto 96-well plates in a 
final volume of 100 µl per well. At each time point, culture medium was replaced with 
100 µl of 5 mg/ml 3-(4,5-dimethylthiazol-3-yl)-2,5-diphenyl tetrazolium bromide. Four 
hours later, the formazan dye was solubilized and read at 490nm optical density as 
described (Denizot and Lang, 1986). Each assay was performed three times in triplicate. 
HepG2 spheroids were trypsinized and proliferation was similarly analyzed. For in vitro 
chemotherapy assays, HepG2 cells were transduced with AdsSPARC, Ad-βgal or left 
non transduced for 2 days, washed and further incubated for 24 h with no 5-FU or with 
different doses of 5-FU ranging from 0.1 to 10 µg/ml. Cell viability was assessed by 
MTT assay as described above.  
Morphological changes associated with apoptosis were assessed by acridine orange-
ethidium bromide mixture staining (Sigma). Single cell suspensions were stained with 
10 µg/ml of the mixture and cells were visualized under a fluorescence microscope. 
Apoptotic cells were defined as those stained in yellow and showing cytoplasmic and 
nuclear shrinkage and chromatin condensation or fragmentation. At least 100 cells were 
counted from 4 independent experiments and the percentage of apoptotic and necrotic 
cells was determined. Apoptosis analysis was performed on HepG2 cells infected with 
AdsSPARC, Ad-βgal or left uninfected by flow cytometry at 48 h using an apoptosis 
detection kit based on annexin-V staining (eBioscienceTM, SanDiego, CA). Briefly, 
HepG2 cells (1x106) were collected with EDTA, washed twice in PBS, centrifuged and 
incubated with 5µl of annexin-V in binding buffer at room temperature for 15 min. 
Cells were vortexed and centrifuged, and the resultant pellets were washed and stained 
with 1µl propidium iodide in binding buffer. The percentage of apoptotic cells were 
immediately analyzed in a FACSCalibur (Becton Dickinson). Results are representative 
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of 4 different experiments. For quantifications, mean values from each independent 
experiment were normalized to their respective control values, prior to statistical 
comparisons.  
 
Cell cycle analysis  
For cell cycle analysis, 2x106 cells were collected, washed in PBS and fixed in a 
mixture of ice-cold 70% (v/v) ethanol, FBS and distill water. Fixed cells were 
centrifuged and stained with propidium iodide (PI) solution (50 mg/ml PI, 180 U/ml 
RNAse). DNA content was determined using a FACScan flow cytometer (Becton 
Dickinson Immunocytometry Systems, San Jose, CA, USA). 
 
Colony formation and cell migration assay. 
For colony formation assay, 1x103 HCC cells (HepG2, Hep3B and Huh7) left untreated 
(control) or transduced with AdsSPARC, AdasSPARC or Ad-βgal were plated onto 60-
mm dishes and incubated for 2 weeks before staining with crystal violet. Colonies, 
composed by 20-25 cells, was quantified under phase-contrast light microscopy. Three 
independent experiments were performed, in triplicates. For transwell cell migration 
assays, non-transduced or AdsSPARC or Ad-βgal transduced HepG2 or Huh7 cells 
(5x104 in 100 µl of 0.1% FBS DMEM) were seeded on the upper chambers of 48-well 
chamber plates (Neuroprobe). In the lower chamber, 5 ng/ml TGF-β1 was added as the 
chemoattractant. After 16 hours incubation at 37°C in 5% CO2, the cells that remained 
on the upper surface of the membrane were removed by wiping with a cotton bud.  
Migrated cells attached to the lower surface of the membrane were fixed with 2% 
formaldehyde/PBS and stained with 10% May Gründwald-Giemsa. The number of 
migrated cells on each membrane was counted under a microscope (x100), for ten 
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random microscopic fields per membrane, and averaged. In order to analyze the 
differential adhesive capacity of treated cells onto polycarbonate membranes, HepG2 
cells were seeded on the upper chambers and four hours later, the cells attached to the 
upper surface of the membrane were fixed and stained.  
 
Western blot analysis. 
Human SPARC was detected in supernatants by monoclonal anti-SPARC antibody 
(diluted 1:500). Supernatants were collected and centrifuged twice at 4ºC for 20 min at 
10000 x g. After centrifugation, cleared supernatants were stored at -80ºC until analysis. 
E-cadherin was detected in HepG2 extracts by mouse monoclonal anti-E-cadherin 
antibody (diluted 1:2000; kindly provided by Dr Berasain,University of Navarra). 
Briefly, cells were collected and incubated in lysis buffer with protease inhibitors 
(50mM Tris-HCI buffer, ph7.4, containing 0.1%Tween-20, 150mM NaCl, 10μg/ml 
aprotinin, 5μg/ml leupeptin, 1mM PMSF) 30 min on ice. Measurement of total protein 
concentration was performed using Bradford assay 45. For immunoblotting, 100 μg of 
total protein was loaded and separated on 10% SDS-PAGE gels and transferred to 
polyvinylidene difluoride membranes as described previously 31. Blots were then 
developed with HRP-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Labs, 
West Grove, PA) diluted 1:5000 in blocking buffer 31. Bands were detected using the 
ECL detection system. Protein loading and transfer for E-cadherin was monitored using 
an anti-actin antibody (diluted 1/700, Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
and incubated with horseradish peroxidase-conjugated goat anti-mouse antibody 
(diluted 1/5000, Santa Cruz Biotechnology, Santa Cruz, CA, USA). For SPARC protein 
loading membranes were stained with Ponceau Red. Bands intensities were measured 
by densitometer analysis using the Scion Image software (Scion Corporation, USA).  
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N-cadherin flow cytometry. 
For flow cytometry analysis, HepG2 cells grown for 48 and 72 h in medium 
supplemented with 2% FBS were washed and detached with 1.25 mM EDTA in PBS. 
After washing with ice-cold medium, cells were incubated with 2 mg/mL of a 
monoclonal anti-N-cadherin antibody (anti-A-CAM, clone CG-4, Sigma, St. Louis, 
MO) for 30 min, washed twice with PBS 0.1% BSA. After washings, samples were 
incubated for 30 min with a secondary goat FITC-conjugated anti-mouse IgG antibody 
(Jackson Immuno Research, West Grove, PA) and fixed in 4% w/v paraformaldehyde in 
PBS for 10 min at room temperature. Cells were washed, resuspended in PBS and 
subjected to flow cytometry using a FACSCalibur (Becton Dickinson) flow cytometer.  
 
Animal studies. 
For assessment of the in vivo tumor growth, HepG2 or HuH7 HCCs were left 
untransduced or were ex vivo-transduced with AdsSPARC, AdasSPARC or Ad-βgal, at 
a MOI of 100. Twenty hours later, cells were trypsinized, counted, and resuspended in 
100 µl of saline. Six- to 8-week-old male athymic N:NIH(S)-nu mice were 
subcutaneously injected into the right flank with 1.5x106 HepG2 cells or 5x106 Huh7  
cells. Perpendicular diameters were used to determine tumor volume (V=(dlxds2x0.52), 
where ds is the smaller diameter and dl is the larger one. Ten animals were allocated to 
each treatment group. For histological analysis, tumor tissue was obtained at day 5 post 
HCC cells inoculation. All procedures were performed according to the "Guide for the 
Care and Use of Laboratory Animals" published by the U.S. National Research Council 
(National Academy Press, Washington, D.C. 1996) and approved by the School of 
Biomedical Sciences of the Austral University. 
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Histology and immunocyto/histochemistry 
Tumor sections from individual mice were fixed in 10% formalin, embedded in 
paraffin, sectioned, and stained with hematoxylin-eosin for morphological evaluation.  
Five-micrometer-thick tumor sections were de-paraffinized in xylene and rehydrated in 
graded ethanol. Endogenous peroxidase activity was blocked by incubating with 3% 
hydrogen peroxide in methanol for 20 minutes. Nonspecific primary antibody binding 
was blocked by incubating sections in normal goat serum (10% in PBS). Endogenous 
biotin and avidin was blocked with blocking agent complex (Vectastain ABC Elite; 
Vector Labs., Burlingame, CA). For detection of macrophages, tissue sections were 
incubated with a rat anti-F4/80 monoclonal antibody (1:100; Serotec) overnight at 4ºC 
in PBS containing 0.1% triton 0.1% bovine serum albumin. Slides were incubated with 
peroxidase-linked biotinylated goat anti-mouse secondary antibodies for 60 min, 
washed and further incubated with the ABC kit (Vector Laboratories). Sections were 
washed and incubated in a mixture of 3.3-diaminobenzidine (DAB) and nickel-
ammonium salt for enhancement of the signal 46. Controls for immunostaining 
specificity in which the primary antibody was replaced by non-immune mouse serum or 
omitted, were negative. Quantitative analysis of immunohistochemical staining for 
F4/80 was performed using the ImageJ software, from 400x magnification images.  
For N-cadherin and smooth muscle actin (SMA) immunocytochemistries, 1000 HepG2 
cells/well were plated onto poli-L-lysine/fibronectin coated coverslips placed on 24-
well plates for 8 hours and then fixed in 4% paraformaldehyde. Cells were incubated 
overnight with a mouse anti-N-cadherin antibody (1:50; Zymed) or a mouse anti-α-
SMA (1:200, Sigma), and specific antibody binding was evidenced by incubation with a 
donkey anti-mouse secondary antibody (1:50; Jackson Immunoresearch) followed by 
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chromogenic reaction (ABC kit, Vector Laboratories) with nickel salt enhancement of 
the signal 46. At least two independent experiments were performed, with similar results. 
For quantifications, only spread cells were considered. The N-cadherin and α-SMA 
immunostaining intensities were measured using the ImageJ software by analyzing 20 
randomly sampled cells per condition. For this purpose, a mean intensity value per cell 
was obtained from 5 random values taken from similar areas of the cytoplasm. Cell 
morphology was determined by establishing similar cultures of HepG2 cells after 16 
hours of incubation.  
 
In vivo apoptosis. TUNEL assay. 
For apoptosis assay, 5-micrometer-thick tumor sections were fixed with 10% formalin 
for 20m and the terminal deoxynucleotidyl transferase–mediated DUPT nick-end 
labeling (TUNEL) assay was done following the manufacturer’s protocol (Fluorescein-
FragEL™ DNA Fragmentation Detection Kit, Calbiochem, Darmstadt, Germany). 
TUNEL-positive cells were analyzed by using a standard fluorescein filter (465-495) 
and were viewed with a microscope (Nikon). 
 
Statistical analysis. 
Data are expressed as mean ± SEM. Statistical analysis was performed using Student's t, 
Mann-Whitney tests or Kruskal-Wallis, when appropriate. Differences at P<0.05 were 
considered to be significant. Survival rates were calculated with the Kaplan–Meier 
method and their differences were evaluated by the log-rank test. Data analysis was 
performed with the Prism GraphPad (GraphPad Software, Inc., San Diego, CA). 
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RESULTS.  
Endogenous SPARC overexpression inhibits HCC cell spheroid growth. 
As shown by western blot (Fig. 1A) and by immunofluorescense (Fig. 1B), SPARC 
expression was identified in HepG2 cells. AdsSPARC transduction (MOI 100) resulted 
in a significant SPARC overexpression at 3 days after gene transfer (Figure 1A).  
To establish the role of SPARC overexpression in HCC cells we initially performed in 
vitro studies growing HCC cells in tri-dimensional spheroids. A profound inhibitory 
effect on spheroid growth of HepG2 cells was observed following SPARC 
overexpression (Figure 2A, upper panel; 2B). On the contrary, transduction of HCC 
cells with Ad-βgal or AdasSPARC had no effects on spheroid growth capacity 
comparable to untransduced cells. Interestingly, when HepG2 cells were exogenously 
treated with recombinant SPARC (Figure 2C) spheroid growth rate was not affected, 
indicating that only endogenous increased levels of this protein was able to induce the 
inhibitory effects on HCC growth. A similar inhibition in spheroid growth formation 
was found in SPARC-overexpressing Hep3B cells (Figure 2A, lower panel). 
 
Increased endogenous SPARC expression levels do not affect proliferation of HCC 
cells.  
To examine whether SPARC overexpression on HCC cells (HepG2, Hep3B and Huh7) 
could influence tumor cell substrate-dependent proliferation capacity, cells were 
assessed for their in vitro growth capacity in plastic. No significant differences were 
found in between groups up to 72 h (Figure 3A). Similar results were observed at 120 h 
(not shown). We next aimed to address whether AdsSPARC transduction on HCC cells 
could induce apoptosis. For this purpose, HepG2 cells were stained with acridine 
orange-ethidium bromide mixture solution and they were subsequently visualized under 
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immunofluorescence microscope. SPARC overexpression resulted in a mild and non-
significant increased induction of cellular apoptosis (Fig. 3B). However, this effect was 
shown to be significant by flow cytometry when the annexin V staining was used 
instead (Fig. 3C). Thus, in order to confirm the lack of significant effects of SPARC 
overexpression on HCC cell proliferation and to address the extent of apoptosis events, 
the pattern of cell cycle progression was analyzed. No differences were found among 
treatments (Fig. 3D). Similarly, when cell cycle analysis was performed on Hep3B cells 
no differences were found in between conditions (G1 phase= 55.5%, 61% and 66%; S 
phase = 35.6%, 31% and 24.5%; G2 phase= 8.9%, 7.2% and 9.1%; for untransduced, 
Ad-βgal and AdsSPARC transduced cells, respectively). Since both the proliferation 
rate and the cell cycle pattern remained unaffected, we conclude that SPARC 
overexpression-mediated increase in HCC cellular apoptosis was not remarkable in 
terms of substrate-dependent cell growth.  
We next wonder whether substrate-independent growth of HCC cells might be 
influenced by SPARC overexpression. To address this issue, HepG2 cells were grown 
in spheroids. Interestingly, and contrarily to what we have observed in monolayer-
cultured HCC cells, a significant reduction in proliferation activity was observed in 
spheroids composed by AdsSPARC-treated cells (Fig. 3E). In order to exclude the 
partial involvement of indirect mechanisms mediated by cellular apoptosis, HepG2 
spheroids were dissociated and stained with acridine orange-ethidium bromide mixture 
solution. No significant differences were found, which overall suggests that an increase 
in endogenous levels of SPARC in HCC cells reduces their substrate-independent 
proliferation capacity, therefore resulting in a partial inhibition of their tridimensional 
growth capacity.  
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Clonogenic and migratory capabilities of HCC cells are inhibited by SPARC over-
expression. Possible implications on HCC cell aggressiveness. 
To assess whether SPARC overexpression in HCC cells might affect their colony 
formation capacity, a feature of cell aggressiveness, cells were plated at a density of 103 
cells per 60-mm dish. After 15 days of incubation, the number of colonies was 
significantly decreased (16-fold) in cells with forced SPARC overexpression when 
compared with Ad-βgal- or AdasSPARC-treated cells (Figure 4A).  
Considering the ability of SPARC to modulate adhesiveness of certain tumor cells, we 
next wonder whether the increased SPARC expression in HCC cells could affect cell 
adhesiveness. For this purpose, cells were placed on fibronectin for 4 hours. AdsSPARC 
overexpressing cells showed a reduced ability to adhere to fibronectin (data not shown).  
Migration is considered to be a critical mechanism in tumor cell dissemination. SPARC 
was previously shown to act as a chemotactic factor for prostate and breast carcinoma 
cell migration towards bone extracts 47, 48; nevertheless, endogenous SPARC expression 
was reported to have opposite effects in glioma cells 49 or to render no effects on MDA-
MB-231 breast cancer cells 50. Therefore, we decided to explore whether overexpression 
of SPARC might affect HCC cells chemotactic capacity towards TGF-β1. As shown in 
figure 4B, AdsSPARC-HepG2 cells exhibited significantly less chemotactic migration 
capacity than cells transduced with Ad-βgal or untransduced cells. Similar results were 
obtained when Hep3B cells were used instead (not shown). Importantly, no differences 
in transwell membrane adherence of HepG2 cells were found among conditions. 
Therefore, the reduced migration capacity of SPARC-overexpressing cells seems not to 
be principally related to differential adherence of HCC cells (Fig.4B upper).Thus, 
overall these data, including colony formation capacity, cell adhesiveness and cell 
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migration capacity results, suggest that intracellular SPARC overexpression likely 
diminishes the aggressive-like behavior of HCC cells.  
E-cadherins are involved in maintaining the epithelial structure of a number of tumor 
types and their down-regulation was associated with an increased invasiveness of 
human hepatocellular carcinomas 51, 52. In addition, N-cadherin expression is frequently 
induced in highly aggressive tumors 43. To further investigate the potential involvement 
of cadherins in SPARC-induced effects, changes in both E- and N-cadherin expression 
levels were investigated. Western blot analysis of AdsSPARC-HCC cells showed 
increased E-cadherin expression levels at day 3 (Fig. 5A). On the other hand, a 50% 
reduction in N-cadherin cell surface expression levels was observed in AdsSPARC-
transduced HepG2 cells when compared to Ad-βgal-transduced or untransduced cells 
(Fig. 5B and C). A similar degree of N-cadherin inhibition was found in SPARC-
overexpressing HCC cultured cells by immunocytochemistry (Figure 5D-H). To 
confirm the previous result, we have performed another experiment and immunostained 
cultures against α-SMA, another mesenchymal marker. Consistently, α-SMA 
expression was also inhibited in AdsSPARC-treated cells (Figure 5I). From previous 
results, we conclude that SPARC overexpression in HepG2 cells results in the 
upregulation of E-cadherin levels and in the downregulation of N-cadherin as well as of 
α-SMA levels, which further suggest they have acquired a less aggressive phenotype. In 
addition, the finding of cell rounding in HCC overexpressing SPARC could be the 
result of its counteradhesive properties. 
 
Upregulation of SPARC expression decreases HCC cells viability and increases 
their apoptosis in response to 5-FU-based chemotherapy. 
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HCC cells are naturally resistant to any chemotherapeutic drug. One of the proposed 
mechanisms responsible for the observed antitumoral effects of SPARC is its ability to 
induce apoptosis of cancer cells 29. In order to assess whether SPARC overexpression 
might led HCC cells more susceptible to chemotherapeutic agents, we tested the effects 
of 5-FU and adriamycin on HepG2 cells proliferation capacity and cell apoptosis. 
SPARC overexpression resulted in an increased sensitivity to 5-FU chemotherapy since 
both a 50% decreased cellular viability (Fig. 6A) and an increased apoptosis (~70% at 
10 µg/ml 5-FU) (Fig. 6B) were observed. No changes were found when adriamycin was 
used as a chemotherapeutic agent instead (not shown).  
 
The in vivo growth capacity of SPARC-overexpressing HCC cells is strongly 
inhibited in nude mice.  
We aimed to explore whether transient SPARC overexpression in two different HCC 
cell lines might affect their in vivo growth. Nude mice injected with control HepG2 cells 
showed an average tumor volume of 500-600 to 900 mm3 at day 40. Contrarily, 
transient overexpression of SPARC in HepG2 cells significantly inhibited tumor growth 
(reaching an average maximum tumor volume value of 30 mm3) (Figure 7A) and 
significantly increased animal survival (log rank test p<0.05) (Figure 7B). No effects in 
vivo were observed on tumor growth upon transient SPARC downregulation. Similar 
results although less potent resulted when Huh7 HCCs were used instead, with an 
increased in animal survival (Figure 7C and D). H&E staining of HepG2 tumors 
overexpressing SPARC showed a decreased rim of viable tumor cells in comparison 
with tumors of untransduced or Ad-βgal- or AdasSPARC treated cells (Figure 8A and 
not shown). In addition, we have observed a reduced number of cells with fibroblast 
morphology in the AdsSPARC-HCC treated group in comparison with controls. 
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Over-expression of SPARC in HCC cells results in increased macrophage 
infiltration.  
Considering the importance of macrophages in the progression of tumors, we assessed 
their possible involvement in the in vivo observed SPARC effects. Interestingly, the 
number of infiltrating macrophages (F4/80+ cells) was significantly higher in 
AdsSPARC-HepG2 HCC tumors in comparison with control animal groups (F4/80 
labeled area: 56463±7209 vs. 17072±2767 vs. 20785±2634 pixels2; AdsSPARC vs. Ad-
βgal vs. Control; p<0.0001; Fig.8B). Significantly higher numbers of F4/80-positive 
cells were found in the core region of tumors from AdsSPARC-treated animals than in 
those from mice injected with HepG2 or Ad-βgal HepG2 cells (Figure 8D). This feature 
could be a consequence of enhanced tumor cell apoptosis, since an increase in apoptosis 
induction was observed by TUNEL in SPARC overexpressing tumors (Figure 8C). 
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DISCUSSION.  
In this paper, we provide for the first time, clear evidence that SPARC has a role on the 
invasive potential of HCC. Transient, overexpression of SPARC in HCC cells 
transduction resulted in a phenotype indicative of decreased tumor cell aggressiveness. 
Moreover, increases endogenous SPARC expression in HepG2 cells resulted in: i) 
reduced capacity to form three-dimensional spheroids and decreased substrate-
independent proliferation, ii) decreased ability to migrate and to generate cellular 
colonies; iii) increased expression of E-cadherin and a concomitant decrease in N-
cadherin expression, iv), increased susceptibility to 5-FU-based chemotherapy and v) a 
potent inhibition of tumorigenicity in vivo leading to increased animal survival. The 
results from key experiments were also confirmed in other two HCC cell lines (Hep3B 
and Huh7) demonstrating that these findings do not correspond to cell specific 
phenomena.  
HCC is a complex disease that often progresses as a consequence of genetic anomalies 
in cancer cells affecting many cell-growth regulatory pathways and also as a result of 
tumor cell interactions with microenvironmental factors 53. In this context, we have 
addressed the role of SPARC, a matricellular glycoprotein with a complex regulatory 
function associated with increased aggressiveness in a number of human cancers 54. 
There is contrasting evidence in the literature regarding SPARC influence on cancer cell 
behavior 54. Although SPARC has been shown to be expressed by cancer cells, in 
certain tumors it is produced as well and at much higher levels by fibroblasts and 
endothelial cells 55. SPARC is almost undetectable in normal hepatic tissue by 
immunohistochemistry, whereas substantial induction of its expression is observed in 
the HCC stroma 37. Our data indicate that only endogenous increased levels of SPARC 
could exert a beneficial effect on HCC growth. Even though there is abundant 
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information on the role of SPARC in other cancer types 23, little is known about its 
involvement in hepatocarcinogenesis. 
In order to analyze the effects of increasing SPARC expression levels on HCC cells we 
chose to take advantage of available gene therapy vectors 56. Among them, replication 
deficient-recombinant adenoviruses have been widely used for gene transfer to the liver 
and especially for HCC experimental treatment 57-59. In particular, Type 5 adenoviruses 
very efficiently infect hepatic cells including HCC cells 59, 60.   
SPARC has been previously shown to induce the inhibition of cancer cells 
proliferation61, arresting cells at G0. The mechanisms by which SPARC inhibits 
proliferation were previously associated with alteration of growth factor signaling 
events through diverse mechanisms including interaction with PDGF receptors 62 with 
the result of Mitogen-Activated Protein Kinase (MAPK) inhibition, cyclin E-Cyclin 
Dependent Kinase 2 (CDK2) inactivation, cyclin A down-regulation, and maintenance 
of RB activation 18. Anti-proliferative effects of SPARC were also associated with 
indirect effects on IGF signals 63. Interestingly, we show here that SPARC 
overexpression in HCC cells did not affect substrate-dependent cell proliferation. In 
addition, SPARC overexpression has been shown to slightly induce cellular apoptosis in 
HepG2 cells. It is noteworthy that the AdsSPARC-mediated induction of SPARC 
inhibited spheroid formation of HCC cells, whereas its knock-down using SPARC 
antisense mRNA had no effects on spheroid growth. Moreover, when cultured as 
monolayer and even though cellular growth was unaffected by SPARC overexpression 
(not shown), a clear inhibitory effect on their clonogenic capacity was noted. 
Furthermore, no effects on spheroid growth were observed when recombinant SPARC 
was exogenously applied, indicating that SPARC effects on HCC tumor cells largely 
rely on the modulation of its cellular levels. 
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Migration is a key step for the invasive and disseminating capabilities of cancer cells. In 
our study, forced upregulation of SPARC expression inhibited migration of HCC cells 
towards TGF-β1, used as a chemoatractant. Although the mechanisms have been 
unknown, some evidences in glioma cell lines suggested that cell migration capability 
may depend on the type of extracellular matrix proteins present in their 
microenvironment (41).  
One of the key processes providing cancer cells with the capacity to migrate, invade and 
metastasize is their ability to undergo an epithelial to mesenchymal transition (EMT) 64. 
EMT is characterized by loss of intercellular adhesion (E-cadherin to N-cadherin 
swicht) 64, downregulation of epithelial markers (cytokeratins), upregulation of MMP-2 
and MMP-9 and the acquisition of a fibroblast-like motile phenotype. In fact, the 
induction of an EMT has been implicated in the malignant progression of HCC 41, 42. 
We observed that SPARC overexpression resulted in E-cadherin upregulation and N-
cadherin downregulation as well as in a reduced expression of α-SMA protein 
altogether suggesting the involvement of mesenchymal to epithelial transition (MET) 
events. However, no significant changes were observed on MMP-2 and MMP-9 
activities which might be due to low frequency of EMT events in HepG2 cells as 
suggested by the low levels of N-cadherin expression found in this specific cell line (not 
shown). These data are in contrast with our and others previous observations in 
melanoma cells, in which high levels of SPARC are associated with N-cadherin 
upregulation and E-cadherin downregulation 65, 66; however, they are consistent with the 
increase of tumor aggressiveness observed in other melanoma models when SPARC is 
overexpressed 30, 31 Thus, SPARC overexpression in different kinds of cancer cells 
seems to be differently involved in modulating EMT or MET, likely affecting cells 
migratory properties. Together, our data suggest that SPARC overexpression in HCC 
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cells induces a MET in HCC cells, a mechanism which is likely involved in differences 
in cell behavior hereby shown, which are indicative of a less aggressive-like phenotype.  
Many chemotherapeutic agents have been applied in the treatment of HCC 67. High 
doses of chemotherapeutic drugs are necessary to obtain a low rate of response. One of 
the chemotherapeutic agents most extensively studied is 5-FU, a pyrimidine 
antimetabolite which has an overall response rate lower than 10% 67. Chemotherapy in 
cirrhotic patients is poorly tolerated and it is no longer applied to patients with advanced 
or metastatic HCC 67. It is clear that there is a need for new non-toxic agents or new 
strategies that can re-sensitize HCC cells to standard chemotherapy. Based on the 
present data SPARC appears to function as a tumor suppressor in some cancer cells and 
one of the mechanisms is the induction of cellular apoptosis. For instance, SPARC has 
been shown to reverse chemotherapy resistance in colorectal carcinoma cells through 
induction of caspase-8 activation 29. Consistent with those results, we found that 
SPARC overexpression in HCC cells resulted in a decreased proliferation and increased 
apoptosis when cells were subjected to lower concentrations of 5-FU. This evidence 
provides a proof-of-principle that the reversal of resistance to 5-FU-based chemotherapy 
can potentially be exploited therapeutically for HCC. Thus, increasing SPARC 
expression on HCC cells through gene therapy could be an attractive strategy to render 
cells more susceptible to standard chemotherapy or to combined treatments. 
Confirming previous results 22, nude animals inoculated with SPARC-overexpressing 
HCC cells showed a strong inhibition of tumor and significant increase in long-term 
survival when compared to controls. In agreement with in vitro effects, knock-down of 
SPARC had no effects on in vivo tumor growth. It still remains unclear to a certain 
extent why SPARC is able to inhibit tumor growth in certain types of tumor while in 
others it has the opposite effect 23. The timing of SPARC expression might partially 
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explain those contrasting results; thus, in our work, high but transient SPARC 
overexpression seems to be a sufficient stimulus to decrease the aggressive-like 
behavior of HCC cells. The induction in E-cadherin and downregulation of N-cadherin 
by SPARC overexpression might be partially involved in the decreased growth ability 
of tumor cells likely through interfering with other microenvironmental factors in the 
cell-cell context. We observed that the density of host tumor invading macrophages is 
increased in AdsSPARC-HCC cells treated animals. This feature might be the 
consequence of in vivo apoptosis induction in SPARC overexpressing HCC cells and/or 
it could be an active event mediated by the enhancement in SPARC expression. Another 
particular observation emerging from histological analysis of HCC tumors is the 
reduced number of cells with fibroblast morphology in the AdsSPARC-HCC treated 
group, suggesting that SPARC might have a role in extracellular matrix organization 
and/or fibroblast invasiveness to tumor mass periphery. On the other hand, only mild 
changes in tumor vasculature were observed after CD31 or von-Willebrand 
immunostainings, at 5 days after tumor cell injection, although it is well known that 
SPARC has antiangiogenic properties. 
In summary, our study implicates SPARC as a HCC tumor modulator protein able to 
inhibit volumetric tumor growth both in vitro and in vivo and to influence several other 
morphological and behavioral cellular features intimately linked to cancer cell 
aggressiveness. In addition, we show that SPARC overexpression in HCC cells likely 
increase tumor cells sensitivity to 5-FU-based chemotherapy. For previous reasons, the 
enhancement of SPARC expression in HCC cells is proposed as a potential strategy for 
the treatment of HCC, a disease in which other therapeutic approaches are nowadays 
mostly neglected.  
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FIGURE LEGENDS. 
Figure 1. Overexpression of SPARC by AdsSPARC. 
Western blot analysis of SPARC on HepG2 hepatocellular carcinoma cells. AdsSPARC 
(at MOI 100) induces high levels of secreted SPARC. A) Western blot of conditioned 
media obtained from HepG2 cells following transduction with the different adenoviral 
vectors. Samples were collected at day 3 after cell transduction. B) Immunofluorescent 
staining of HepG2 naïve cells. Fluorescence signals specific to SPARC antibody are 
visualized in green and nuclei, in blue (DAPI staining).  
 
Figure 2. Positive modulation of SPARC levels strongly inhibits HCC multicellular  
spheroid growth. 
A) Spheroids prepared from HepG2 (upper panel) and Hep3B (lower panel) cells were 
transduced with AdsSPARC, AdasSPARC or Ad-βgal. Comparisons of spheroid mean 
volumes at days 2 and 6. Data expressed as the mean ± SEM correspond to 3 
experiments performed in 5 replicas. (*) vs. Ad-βgal. (*) <0.05 using Mann-Whitney 
test. B) Photographs of the spheroids from HepG2 cells at day 6, taken under phase-
contrast light microscopy. C) Exogenous administration of SPARC as a recombinant 
protein did not affect spheroid growth on HepG2 cells. Kruskal-Wallis showed no 
significant differences among groups. 
 
Figure 3. SPARC upregulation does not profoundly affect HCC cell growth in 
vitro. 
A) HCC cells (HepG2, Hep3B and Huh7) were incubated with no addition of viral 
vectors or with AdsSPARC, AdasSPARC or Ad-βgal for 3 days, at a MOI of 100. Cell 
viability was determined by MTT assay (Invitrogen) at 490 nm, in 3 independent 
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studies; ns: non-significant. (*) p<0.05 using Mann-Whitney test. B) SPARC 
overexpression results in a non-significant increase in HepG2 cellular apoptosis when 
analyzed by the acridine-orange/ethidium bromide method. (*) p<0.05 using Mann-
Whitney test. C) Flow cytometric analysis of HepG2 cells stained with annexin-V 
obtained after 72 hours in culture showed a slight significant induction in cellular 
apoptosis in SPARC overexpressing cells. Results are representative of 4 experiments 
similarly performed. (*) p<0.05 using Mann-Whitney test. D) Cell cycle analysis from 
DNA content. Cell cycle profiles correspond to one representative experiment of the 
three that were performed. Values are expressed as mean ± SEM. E) Proliferation 
activity of cells grown in spheroids, analyzed by MTT. (*) p<0.05 using Student's t test.  
 
Figure 4. SPARC profoundly influences colony formation and migratory 
capability in HCC cells. 
A) AdsSPARC reduced HCC cell clonogenic capacity. For colony formation assay 103 
untreated (Control) or AdsSPARC, AdasSPARC or Ad-βgal transduced (MOI 100) 
HCC cells (HepG2, Hep3B and Huh7) were cultured in a 6-well plate for 2 weeks 
before crystal violet staining, and the number of colonies (20-25 cells) was quantified 
under phase-contrast light microscopy (*) P < 0.05 vs. Control; Mann-Whitney test. B) 
AdsSPARC inhibits migration towards TGF-β1 of HepG2 cells. HepG2 cells were 
transduced with AdsSPARC or Ad-βgal or left untransduced for 3 days at a MOI of 
100. Migration assays were performed in the absence of FBS as described in M&M. 
Transwell cell migration analysis was performed using 5 ng/ml TGF-β1 as 
chemoattractant. Cells on the back of the insert membrane were fixed and stained with 
10% May Grunwald-Giemsa. Representative pictures of transwell membrane adherence 
of HCC cells are shown (x200). For quantification, the average number of migrated 
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cells per field was assessed. (***) P < 0.001 vs. Control and Ad-βgal; Student's t test. 
All assays were done in triplicate. 
 
Figure 5. Gene transfer of SPARC induces mesenchymal -to- epithelial  transition 
in hepatocellular carcinoma cells.  
A) HepG2 cells were infected (at a MOI of 100) with AdsSPARC, AdasSPARC or 
Adβgal for 3 days and whole-cell lysates were generated. E-cadherin expression was 
assessed by western blot. A representative of three independent experiments is shown. 
A goat antibody against actin was used as control of protein loading. B) SPARC 
overexpression induces a decrease of N-cadherin expression in HepG2 cells. HepG2 
cells were infected (at a MOI of 100) with AdsSPARC or Ad-βgal for 3 days, fixed and 
incubated with antibodies to N-cadherin. By using fluorescence-activated flow 
cytometry analysis, N-cadherin expression is displayed by a shift in mean fluorescent 
intensity when compared to incubation without addition of any primary antibody. The 
percentages of N-cadherin positive cells are indicated. C) Quantitative analysis from 
comparisons of results obtained from independent studies similar to that shown in B). 
D, E, F, G) Representative pictures from N-cadherin immunostained HepG2 cells, 
which were previously transduced with AdsSPARC (D,E) or Ad-βgal (F,G) and plated 
onto poli-L-lysine/fibronectin coated coverslips. H, I) Quantification of the N-cadherin 
(H) and α-SMA (I) immunostaining intensities in HepG2 cells is represented. The data 
are expressed as the Mean ± SEM. (*) vs. Control; (τ) vs. Ad-βgal. (*) p<0.05; (ττ) 
p<0.01; (***,σσσ) p<0.001. Student's t test. 
 
Figure 6. Up-regulation of SPARC expression decreases HCC cell viability in 
response to 5-FU-based chemotherapy and increases apoptosis.   
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A) HepG2 cells were infected with AdsSPARC, Ad-βgal or left uninfected for 2 days, 
washed and further incubated with 5-FU for 24 h. Cell viability was assessed by MTT 
assay (Invitrogen) at 490 nm. The data is expressed as the mean absorbance ± SEM. B) 
HepG2 cells were infected with AdsSPARC, Adβgal or left uninfected for 2 days, 
washed and further incubated with 5-FU for 24 h and stained with an AO/EB bromide 
mixture. Percentage of apoptotic cells is shown. The data are expressed as the Mean ± 
SEM. (*) vs. Control; (σ) vs. Ad-βgal. (*,σ) p<0.05; (**,σσ) p<0.01; (***,σσσ) 
p<0.001. Student's t test. 
 
Figure 7. The in vivo growth capacity of SPARC overexpressing HCC cells is 
strongly inhibited in nude mice.   
AdsSPARC significantly increased animal survival. Nude mice were s.c. inoculated 
with 1.5x106 HepG2 (A) or 5x106 Huh7 (C) cells transduced with AdsSPARC or 
AdasSPARC or Ad-βgal or left untransduced and tumor size was measured with caliper 
twice a week over a period of 42 days. Effects of AdsSPARC treatment on survival of 
the tumor-bearing nude mice (B, HepG2 cells; D, Huh7 cells) (Kaplan-Meier survival 
curve). The data are expressed as the Mean ± SEM. (*) vs. Control; (σ) vs. Ad-βgal. 
(*,σ) p<0.05; (**,σσ) p<0.01; (σσσ) p<0.001. Mann-Whitney test. 
 
Figure 8. Host macrophage cells are involved in the rejection of SPARC 
overexpressing HCC cells. Nude mice were s.c. inoculated with 1.5x106 HepG2 cells 
transduced with AdsSPARC, AdasSPARC, Adβgal or left untransduced. A) H&E 
staining showing a reduced tumoral rim in mice from AdsSPARC group. Arrows: 
fibroblastic-like cells; dotted arrows: tumor cells. B) Representative photographs of 
immunohistochemical staining of macrophages (F4/80) in HepG2 tumors at 5 days after 
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inoculation, corresponding to HepG2 (upper, 100x; lower, 400x) and AdsSPARC-
HepG2 (upper, 100x; lower, 400x) treated mice. C) Quantitative graph showing 
comparisons of the F4/80 immunostained area in different experimental conditions. The 
data are expressed as the Mean ± SEM. (*) vs. Control; (σ) vs. Ad-βgal. (*,σ) p<0.05; 
(**,σσ) p<0.01; (***,σσσ) p<0.001. Mann-Whitney test. D) SPARC increases in vivo 
HCC apoptosis. The effect of SPARC overexpression on apoptosis was assessed by 
TUNEL assay. Representative photographs of TUNEL assay in HepG2 tumors at day 5 
after treatment, corresponding to Adβgal, AdsSPARC, AdasSPARC or untransduced 
HepG2 cells.  
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